| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
|
|
| 3. |
- Ogawa, Y., et al.
(författare)
-
On the statistical relation between ion upflow and naturally enhanced ion-acoustic lines observed with the EISCAT Svalbard radar
- 2011
-
Ingår i: Journal of Geophysical Research. - 0148-0227 .- 2156-2202. ; 116, s. A03313-
-
Tidskriftsartikel (refereegranskat)abstract
- We have investigated characteristics of ion upflow and naturally enhanced ion-acoustic lines (NEIALs) based on the European Incoherent Scatter (EISCAT) Svalbard radar (ESR) data continuously obtained between March 2007 and February 2008. For the ion upflow study we have used approximately 78,000 field-aligned profiles obtained with the ESR. For the NEIAL study we have identified approximately 1500 NEIALs in the ESR data at altitudes between 100 and 500 km. The occurrence frequency of ion upflow shows two peaks, at about 0800 and 1300 magnetic local time (MLT), while only one strong peak is seen around 0900 MLT for NEIALs. The upward ion flux also has only one peak around 1100-1300 MLT. The occurrence frequency of ion upflow varies strongly over season. It is higher in winter than in summer, whereas NEIALs are more frequent in summer than in winter. NEIALs frequently occur under high geomagnetic activity and also high solar activity conditions. Approximately 10% of NEIALs in the F region ionosphere were accompanied by NEIALs in the E region (occurred at altitudes below 200 km). About half of the E region enhanced echoes did not have an F region counterpart. Upshifted NEIALs dominate in the E region whereas downshifted NEIALs are usually stronger above an altitude of 300 km. The high occurrence frequency of NEIALs in the prenoon region (0800-1000 MLT) might be associated with acceleration of thermal ions to suprathermal ones. At the same MLT and geomagnetic latitude suprathermal ions and broadband extremely low frequency (BBELF) wave activity have been observed, according to previous studies.
|
|
| 4. |
|
|
